Zydus Cadila, a global pharmaceutical company, has received the final approval from the US Food and Drug Administration (FDA) to market pyridostigmine bromide tablets USP, 60 mg. It is used for treating various neurological disorders.
With this approval, the group has received 100 approvals and has so far filed 260 ANDAs since the commencement of the filing process in FY 2003-04.According to IMS Health data, the estimated sales in 2015 for these tablets was USD 27.9 million.
Subscribe to PharmaTutor News Alerts by Email >>
